BOSTON & EDINBURGH, Scotland--(BUSINESS WIRE)--April 5, 2005--According to a new study by Wood Mackenzie a significant proportion of the US revenues of some major pharmaceutical and biotechnology firms are at risk due to a sharper focus on Part B Medicare drug costs by the Centers for Medicare and Medicaid Services (CMS). Part B drugs, which are administered by doctors and in clinics rather than by patients themselves, make up the majority of the most expensive drugs introduced on the market in recent years, as well as the bulk of biotechnology company pipelines. The study, Medicare Insight, shows that Part B drug prices have historically grown at double the rate of Part D drugs.
